Cannabis Use Was Linked to One Sleep Complaint but Not Others in Older Pain Patients

Sleep is not one interchangeable outcome. A cross-sectional study in older adults with chronic pain linked medical cannabis use to fewer nighttime-waking problems, while other sleep complaints did not differ between users and non-users.

A comparison of existing users and non-users

The study recruited 128 patients over fifty years old, including sixty-six medical cannabis users and sixty-two non-users. Regression analyses accounted for several measured characteristics, including pain and medication use. Participants were not randomized to begin cannabis treatment.

Results differed by the sleep question

After adjustment, cannabis use was associated with fewer problems waking during the night. The abstract reports no group difference in difficulty falling asleep or waking early without returning to sleep. Among cannabis users, more frequent use was associated with greater problems on some sleep measures.

Frequency does not establish the direction of cause

Frequent use might contribute to adaptation, but people with worse symptoms might also use more often. A single cross-sectional assessment cannot establish which came first. Statistical adjustment for measured variables does not remove every difference between people who choose cannabis and those who do not.

The study supports separating sleep onset, nighttime maintenance and early waking rather than declaring that cannabis uniformly improves sleep. It also does not establish a personal dosing schedule, a driving-clearance interval or a causal tolerance mechanism. Clinical and forensic accounts should identify the specific complaint, the treatment history and whether the evidence measures an association or a change caused by treatment.

Related: interpreting cannabis tolerance claims.

Research cited

Sznitman SR; Vulfsons S; Meiri D; Weinstein G. Medical cannabis and insomnia in older adults with chronic pain: a cross-sectional study. BMJ supportive & palliative care (2020). doi:10.1136/bmjspcare-2019-001938. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Pilot Mouse Study Found Declining THC and CBNA Antinociception With Repeated Administration

A 2021 pilot study reported strong initial antinociceptive responses to THC and cannabinolic acid, followed by decreasing responses over subsequent days. The evidence concerns adult male mice and experimental mechanical and thermal tests. The study evaluated two nociceptive domains Mechanical and thermal responses were assessed after systemic intraperitoneal administration. Those…

Spread the love

Read Article: A Pilot Mouse Study Found Declining THC and CBNA Antinociception With Repeated Administration

Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A 2001 mouse study found different opioid- and cannabinoid-receptor protein patterns across midbrain and spinal cord after short-term THC–morphine treatment. A statement about total receptor change would obscure those tissue-specific comparisons. The comparison included separate treatment groups Investigators assessed THC, morphine and their combination using Western blot measurements. Opioid-receptor protein…

Spread the love

Read Article: Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

A 2003 study found that selected kinase inhibitors reversed THC antinociceptive tolerance while others did not. One higher-dose intervention reduced THC's acute antinociceptive effect, illustrating a different outcome from reversing tolerance. The panel included useful negatives The study tested interventions directed at several kinases. Some did not affect tolerance under…

Spread the love

Read Article: A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us